Changes in e25742f: table1

				APOA5.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_APOA5.md]]

				APP.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_APP.md]]

				ARAP2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|

          +[[include:table1_ARAP2.md]]

				ARHGAP20.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|

          +[[include:table1_ARHGAP20.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARHGEF1.md
			
          @@ -10,9 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![BL](images/icons/BL_tier2.png)    |2   |relevance in BL not firmly established[@muppidiLossSignalingGa132014]|

          +[[include:table1_ARHGEF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARHGEF15.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|

          +[[include:table1_ARHGEF15.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARHGEF17.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|

          +[[include:table1_ARHGEF17.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARID1B.md
			
          @@ -11,10 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description                              |

          -|:------:|:----:|-----------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png) |3   |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|

          -|![MCL](images/icons/MCL_tier2.png)   |2   |relevance in MCL not firmly established  |

          +[[include:table1_ARID1B.md]]

           ## Warnings

				ARID5B.md
			
          @@ -11,10 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description                              |

          -|:------:|:----:|-----------------------------------------|

          -|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@gomezUltraDeepSequencingReveals2023]|

          -|![DLBCL](images/icons/DLBCL_tier2.png) |2   |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017;@drevalRevisitingReddyDLBCL2023; @arthurGenomewideDiscoverySomatic2018]|

          +[[include:table1_ARID5B.md]]

           ## Warnings

				ARIH2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|

          +[[include:table1_ARIH2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ASXL3.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@albuquerqueEnhancingKnowledgeDiscovery2017]|

          +[[include:table1_ASXL3.md]]

				ATIC.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_ATIC.md]]

				ATM.md
			
          @@ -15,11 +15,7 @@ Mutations in this gene were first described in MZL by Braggio et al.[@braggioGen

           ## Relevance tier by entity

          -|Entity|Tier|Description               |

          -|:------:|:----:|--------------------------|

          -|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@braggioGenomicAnalysisMarginal2012]|

          -|![DLBCL](images/icons/DLBCL_tier1.png) |1   |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @arthurGenomewideDiscoverySomatic2018]|

          -|![MCL](images/icons/MCL_tier1.png)   |1   |high-confidence MCL gene  [@beaLandscapeSomaticMutations2013]|

          +[[include:table1_ATM.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP1A2.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_ATP1A2.md]]

				ATP2A3.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|

          +[[include:table1_ATP2A3.md]]

				ATP2C2.md
			
          @@ -16,9 +16,7 @@ Due to [minimal support](ATP2C2#representative-mutation) in the original primary

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![BL](images/icons/BL_tier2.png)    |3   |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|

          +[[include:table1_ATP2C2.md]]

           ## Warnings

				ATP6AP1.md
			
          @@ -10,9 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description            |

          -|:------:|:----:|-----------------------|

          -|![FL](images/icons/FL_tier1.png)    |1   |high-confidence FL gene[@okosunRecurrentMTORC1activatingRRAGC2016]|

          +[[include:table1_ATP6AP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP6V0A1.md
			
          @@ -13,9 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -|Entity|Tier|Description|

          -|:------:|:----:|--------------------------------------|

          -|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|

          +[[include:table1_ATP6V0A1.md]]

				ATP6V1A.md
			
          @@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -|Entity|Tier|Description                           |

          -|:------:|:----:|--------------------------------------|

          -|![FL](images/icons/FL_tier2.png)    |2   |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|

          +[[include:table1_ATP6V1A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

...	...	@@ -13,9 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-\|Entity\|Tier\|Description\|
17		-\|:------:\|:----:\|--------------------------------------\|
18		-\|![DLBCL](images/icons/DLBCL_tier3.png)\|3\|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]\|
	16	+[[include:table1_APOA5.md]]
19	17
20	18
21	19

...	...	@@ -10,9 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-\|Entity\|Tier\|Description \|
14		-\|:------:\|:----:\|--------------------------------------\|
15		-\|![BL](images/icons/BL_tier2.png) \|2 \|relevance in BL not firmly established[@muppidiLossSignalingGa132014]\|
	13	+[[include:table1_ARHGEF1.md]]
16	14
17	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18	16

...	...	@@ -11,10 +11,7 @@ nocite: \|
11	11
12	12	## Relevance tier by entity
13	13
14		-\|Entity\|Tier\|Description \|
15		-\|:------:\|:----:\|-----------------------------------------\|
16		-\|![DLBCL](images/icons/DLBCL_tier2.png) \|3 \|Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]\|
17		-\|![MCL](images/icons/MCL_tier2.png) \|2 \|relevance in MCL not firmly established \|
	14	+[[include:table1_ARID1B.md]]
18	15
19	16	## Warnings
20	17

...	...	@@ -15,11 +15,7 @@ Mutations in this gene were first described in MZL by Braggio et al.[@braggioGen
15	15
16	16	## Relevance tier by entity
17	17
18		-\|Entity\|Tier\|Description \|
19		-\|:------:\|:----:\|--------------------------\|
20		-\|![MZL](images/icons/MZL_tier1.png)\|1\|high-confidence MZL gene[@braggioGenomicAnalysisMarginal2012]\|
21		-\|![DLBCL](images/icons/DLBCL_tier1.png) \|1 \|high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @arthurGenomewideDiscoverySomatic2018]\|
22		-\|![MCL](images/icons/MCL_tier1.png) \|1 \|high-confidence MCL gene [@beaLandscapeSomaticMutations2013]\|
	18	+[[include:table1_ATM.md]]
23	19
24	20	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25	21

...	...	@@ -16,9 +16,7 @@ Due to [minimal support](ATP2C2#representative-mutation) in the original primary
16	16
17	17	## Relevance tier by entity
18	18
19		-\|Entity\|Tier\|Description \|
20		-\|:------:\|:----:\|--------------------------------------\|
21		-\|![BL](images/icons/BL_tier2.png) \|3 \|Retired, Failed QC[@loveGeneticLandscapeMutations2012]\|
	19	+[[include:table1_ATP2C2.md]]
22	20
23	21	## Warnings
24	22

...	...	@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
14	14
15	15	## Relevance tier by entity
16	16
17		-\|Entity\|Tier\|Description \|
18		-\|:------:\|:----:\|--------------------------------------\|
19		-\|![FL](images/icons/FL_tier2.png) \|2 \|relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]\|
	17	+[[include:table1_ATP6V1A.md]]
20	18
21	19	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22	20